JP2001513633A - プロコラーゲンの組立て - Google Patents
プロコラーゲンの組立てInfo
- Publication number
- JP2001513633A JP2001513633A JP53740798A JP53740798A JP2001513633A JP 2001513633 A JP2001513633 A JP 2001513633A JP 53740798 A JP53740798 A JP 53740798A JP 53740798 A JP53740798 A JP 53740798A JP 2001513633 A JP2001513633 A JP 2001513633A
- Authority
- JP
- Japan
- Prior art keywords
- chain
- pro
- procollagen
- gene
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010050808 Procollagen Proteins 0.000 title claims abstract description 82
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 57
- 230000000694 effects Effects 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 69
- 229920001436 collagen Polymers 0.000 claims description 42
- 102000008186 Collagen Human genes 0.000 claims description 41
- 108010035532 Collagen Proteins 0.000 claims description 41
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 9
- 238000001415 gene therapy Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 101710096389 Collagen alpha chain Proteins 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 241000289695 Eutheria Species 0.000 claims 1
- 239000000499 gel Substances 0.000 description 23
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 238000013519 translation Methods 0.000 description 18
- 230000014616 translation Effects 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000013638 trimer Substances 0.000 description 13
- 230000035772 mutation Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000001553 co-assembly Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 108010069502 Collagen Type III Proteins 0.000 description 6
- 102000001187 Collagen Type III Human genes 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 5
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 5
- 108090000317 Chymotrypsin Proteins 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 229960002376 chymotrypsin Drugs 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 210000003660 reticulum Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000005829 trimerization reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 108010064622 Procollagen N-Endopeptidase Proteins 0.000 description 2
- 102000015339 Procollagen N-endopeptidase Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101150036477 Gen gene Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 229940043292 chymotrypsin / trypsin Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- MAHNFPMIPQKPPI-UHFFFAOYSA-N disulfur Chemical compound S=S MAHNFPMIPQKPPI-UHFFFAOYSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Vehicle Body Suspensions (AREA)
- Coupling Device And Connection With Printed Circuit (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Mobile Radio Communication Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくとも1つの別のプロコラーゲンまたはその誘導体を共発現して組み 立てるシステムにおいて所望のプロコラーゲンまたはその誘導体を生産する方法 であって、所望のプロコラーゲンを組立てるためのプロ−α鎖またはその誘導体 を発現する遺伝子が、天然のプロ−α鎖から外因的に選択されるか、またはC− 末端プロペプチドドメインの活性を有するが、該少なくとも1つの別のプロコラ ーゲンまたはその誘導体を組立てて形成する、プロ−α鎖またはその誘導体のC −末端プロペプチドと共組立てされないドメインをもつ該プロ−α鎖またはその 誘導体を発現するように人工的に工作される遺伝子であることを特徴とする方法 。 2.遺伝子の少なくとも一部が、プロ−α鎖からプロコラーゲンへの組立てに おける選択性を付与する認識配列をコードする、請求項1に記載の方法。 3.認識配列が、アミノ酸配列 GGQGSDPADV AIQLTFLRLM STE をコードする、請求項2に記載の方法。 4.認識配列が、アミノ酸配列 NVEGVTSKEM ATQLAFMRLL ANY をコードする、請求項2に記載の方法。 5.認識配列が、アミノ酸配列 GDDNLAPNTA NVQMTFLRLL STE をコードする、請求項2に記載の方法。 6.認識配列が、アミノ酸配列 GNPELPEDVL DVQLAFLRLL SSR をコードする、請求項2に記載の方法。 7.認識配列が、アミノ酸配列 VDAEGNPVGV.VQMTFLRLL SAS をコードする、請求項2に記載の方法。 8.認識配列が、アミノ酸配列 GDHQSPNTAI.TQMTFLRLL SKE をコードする、請求項2に記載の方法。 9.認識配列が、アミノ酸配列 LDVEGNSINM.VQMTFLKLL TAS をコードする、請求項2に記載の方法。 10.認識配列が、アミノ酸配列 VDSEGSPVGV.VQLTFLRLL SVS をコードする、請求項2に記載の方法。 11.遺伝子が、1つのプロ−α鎖遺伝子から誘導された認識配列および異な る源から誘導されたα鎖ドメインを含むプロ−α鎖またはその誘導体をコードす る、請求項2〜10に記載の方法。 12.遺伝子が、少なくとも2つの異なるプロ−α鎖のフラグメントから形成 されたプロ−α鎖またはその誘導体をコードする、請求項2〜10に記載の方法 。 13.遺伝子が、1つのタイプのプロ−α鎖およびC−末端プロペプチドドメ インを含むプロ−α鎖またはその誘導体をコードする、請求項11または12に 記載の方法。 14.DNA分子が、proα1(I)、proα1(II)、proα1(III)、proα1(V)、pr oα2(V)、proα1(XI)またはproα2(XI)からなるプロ−α鎖のフラグメントの組 み合わせから形成されたプロ−α鎖またはその誘導体をコードする、請求項11 〜13のいずれか1つに記載の方法。 15.遺伝子が、proα2(I)鎖の認識配列がproα1(III)鎖の認識配列で置換さ れている修飾proα2(I)をコードする、請求項14に記載の方法。 16.遺伝子が、プロコラーゲンC−末端プロペプチドの活性を有する第1部 分および外因的コラーゲンα鎖および非コラーゲン成分のいずれか1つから選択 された第2部分を少なくとも含む(第1部分と第2部分は連結している)、プロ −α鎖またはその誘導体をコードする塩基配列を含む、請求項1に記載の方法。 17.遺伝子がベクターに組み込まれている、前記請求項のいずれかに記載の 方法。 18.ベクターがプラスミド、コスミドまたはファージである、請求項17に 記載の方法。 19.システムが遺伝子でトランスフェクトされた宿主細胞である、前記請求 項のいずれかに記載の方法。 20.宿主細胞が真核細胞である、請求項19に記載の方法。 21.宿主細胞が酵母、昆虫または哺乳動物細胞である、請求項20に記載の 方法。 22.宿主細胞が、哺乳動物細胞であり、線維芽細胞または、ベビーハムスタ ー腎臓細胞,マウス3T3細胞,チャイニーズハムスター卵巣細胞およびCOS 細胞から誘導された細胞系から選ばれる、請求抗21に記載の方法。 23.システムがトランスジェニック植物または動物である、請求項1〜19 に記載の方法。 24.システムがトランスジェニック動物であり、非ヒト胎盤性哺乳動物であ る請求項23に記載の方法。 25.胎盤性哺乳動物が、ウシ、ヒツジ、ヤギ、水牛、ラクダまたはブタのい ずれか1つである、請求項24に記載の方法。 26.システムがトランスジェニック動物であり、遺伝子療法を必要としてい るヒトである、請求項19に記載の方法。 27.遺伝子療法が、骨形成不全症、エーレルス−ダンロー症候群または軟骨 形成異常を治療するためのものである、請求項26に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9704305.3A GB9704305D0 (en) | 1997-03-01 | 1997-03-01 | Procollagen assembly |
GB9704305.3 | 1997-03-01 | ||
PCT/GB1998/000468 WO1998038303A1 (en) | 1997-03-01 | 1998-03-02 | Procollagen assembly |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001513633A true JP2001513633A (ja) | 2001-09-04 |
Family
ID=10808561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53740798A Pending JP2001513633A (ja) | 1997-03-01 | 1998-03-02 | プロコラーゲンの組立て |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050149995A1 (ja) |
EP (1) | EP0972031B1 (ja) |
JP (1) | JP2001513633A (ja) |
AT (1) | ATE507294T1 (ja) |
AU (1) | AU749709B2 (ja) |
CA (1) | CA2282719C (ja) |
DE (1) | DE69842239D1 (ja) |
GB (1) | GB9704305D0 (ja) |
WO (1) | WO1998038303A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108250267B (zh) * | 2018-01-26 | 2021-04-20 | 北京大学深圳研究生院 | 一种多肽、多肽-siRNA诱导共组装体及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501939A (ja) * | 1991-10-23 | 1995-03-02 | トーマス・ジェファーソン・ユニバーシティ | 組み換えdna合成システムにおけるヒトプロコラーゲン及びコラーゲンの合成 |
JPH08506016A (ja) * | 1993-01-28 | 1996-07-02 | コラーゲン コーポレイション | トランスジェニック動物のミルク内のヒト組換えコラーゲンの製造法 |
JP4003836B2 (ja) * | 1995-08-31 | 2007-11-07 | ザ・ユニバーシティ・オブ・マンチェスター | 新規プロコラーゲン |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2109336T3 (es) * | 1990-11-26 | 1998-01-16 | Genetics Inst | Expresion de pace en celulas huesped y metodos de utilizacion de la misma. |
US5593859A (en) * | 1991-10-23 | 1997-01-14 | Thomas Jefferson University | Synthesis of human procollagens and collagens in recombinant DNA systems |
US6653450B1 (en) * | 1993-01-28 | 2003-11-25 | Cohesion Technologies, Inc. | Mutated recombinant collagens |
-
1997
- 1997-03-01 GB GBGB9704305.3A patent/GB9704305D0/en active Pending
-
1998
- 1998-03-02 DE DE69842239T patent/DE69842239D1/de not_active Expired - Lifetime
- 1998-03-02 CA CA2282719A patent/CA2282719C/en not_active Expired - Fee Related
- 1998-03-02 JP JP53740798A patent/JP2001513633A/ja active Pending
- 1998-03-02 AT AT98906998T patent/ATE507294T1/de not_active IP Right Cessation
- 1998-03-02 AU AU62994/98A patent/AU749709B2/en not_active Ceased
- 1998-03-02 EP EP98906998A patent/EP0972031B1/en not_active Expired - Lifetime
- 1998-03-02 WO PCT/GB1998/000468 patent/WO1998038303A1/en active IP Right Grant
-
2003
- 2003-08-04 US US10/632,847 patent/US20050149995A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501939A (ja) * | 1991-10-23 | 1995-03-02 | トーマス・ジェファーソン・ユニバーシティ | 組み換えdna合成システムにおけるヒトプロコラーゲン及びコラーゲンの合成 |
JPH08506016A (ja) * | 1993-01-28 | 1996-07-02 | コラーゲン コーポレイション | トランスジェニック動物のミルク内のヒト組換えコラーゲンの製造法 |
JP4003836B2 (ja) * | 1995-08-31 | 2007-11-07 | ザ・ユニバーシティ・オブ・マンチェスター | 新規プロコラーゲン |
Non-Patent Citations (6)
Title |
---|
JPN4007019057, J.Biol.Chem.,, 1989, Vol.264, No.5, p.2735−2738 * |
JPN4007019058, J.Biol.Chem., 1991, Vol.266, No.36, p.24727−24733 * |
JPN4007019059, J.Biol.Chem., 1986, Vol.261, No.19, p.8924−8935 * |
JPN6009012016, J.Biol.Chem., 1989, Vol.264, No.5, p.2735−2738 * |
JPN6009012020, J.Biol.Chem., 1991, Vol.266, No.36, p.24727−24733 * |
JPN6009012029, J.Biol.Chem., 1986, Vol.261, No.19, p.8924−8935 * |
Also Published As
Publication number | Publication date |
---|---|
ATE507294T1 (de) | 2011-05-15 |
AU749709B2 (en) | 2002-07-04 |
EP0972031A1 (en) | 2000-01-19 |
EP0972031B1 (en) | 2011-04-27 |
US20050149995A1 (en) | 2005-07-07 |
AU6299498A (en) | 1998-09-18 |
CA2282719C (en) | 2012-01-03 |
GB9704305D0 (en) | 1997-04-23 |
CA2282719A1 (en) | 1998-09-03 |
DE69842239D1 (de) | 2011-06-09 |
WO1998038303A1 (en) | 1998-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4003836B2 (ja) | 新規プロコラーゲン | |
Ruggiero et al. | Triple helix assembly and processing of human collagen produced in transgenic tobacco plants | |
Moritz et al. | Molecular cloning, membrane topology, and localization of bovine rom-1 in rod and cone photoreceptor cells. | |
Lewis et al. | Expression and purification of a spider silk protein: a new strategy for producing repetitive proteins | |
Kuivaniemi et al. | Mutations in collagen genes: causes of rare and some common diseases in humans | |
Nokelainen et al. | High‐level production of human type I collagen in the yeast Pichia pastoris | |
Yost et al. | Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein | |
JP2740417B2 (ja) | ヒト神経成長因子の遺伝子組換えによる調製法 | |
KR101700970B1 (ko) | 지혈 활성을 가지고 혈소판 응집을 유도할 수 있는 재조합 단백질 | |
US5610031A (en) | B1k chain of laminin and methods of use | |
JP2010017184A (ja) | ヒトの凝固第viii因子及びフォンビルブラント因子を発現するトランスジェニック動物 | |
JPH09512710A (ja) | 組換えフィブリン鎖、フィブリンおよびフィブリン−ホモログ | |
JPH10502360A (ja) | ヒトインターロイキン4のアンタゴニストもしくは部分的アゴニストとして用いられる新規hIL−4突然変異蛋白質 | |
US6451557B1 (en) | Method for producing, in yeast, a hydroxylated triple helical protein, and yeast host cells useful in said method | |
Illidge et al. | Type VIII collagen: heterotrimeric chain association | |
JPH02501263A (ja) | ヒトの組織因子のクローニングと形質発現 | |
US5460955A (en) | Fibronectin purification vector | |
JP2001513633A (ja) | プロコラーゲンの組立て | |
Doyle et al. | Role of the pro‐α2 (I) COOH‐terminal region in assembly of type I collagen: Disruption of two intramolecular disulfide bonds in pro‐α2 (I) blocks assembly of type I collagen | |
JP2007527204A (ja) | 生理活性な異種ドメインを担持するコラーゲン線維およびその、例えば、創傷の治癒における使用 | |
CN115176019A (zh) | 能够在微藻类的叶绿体中产生胶原蛋白、弹性蛋白及其衍生物的肽、多肽或蛋白质的重组微藻类及其相关方法 | |
JP2002325584A (ja) | 組換えヒトiv型コラーゲンペプチドとその製造方法 | |
Skach | [19] Topology of P-glycoproteins | |
WO2005037852A2 (en) | Trimerizing polypeptides and their uses | |
JPH02227079A (ja) | ヒト血清アルブミン断片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050223 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20090324 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090623 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090724 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090916 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100615 |